22 May 2019 | News
Novo Nordisk will feature 26 presentations throughout the meeting.
Novo Nordisk has announced that new data from its diabetes portfolio will be presented at the upcoming 79th Annual Scientific Sessions of the American Diabetes Association (ADA) in San Francisco, California from June 7-11, 2019. Novo Nordisk will feature 26 presentations throughout the meeting.
Results from seven phase 3a PIONEER clinical trials for oral semaglutide in patients with type 2 diabetes will be presented including the cardiovascular outcomes trial (PIONEER 6) at a highly anticipated symposium highlighted by the ADA on June 11. Oral semaglutide is an investigational glucagon-like peptide-1 (GLP-1) analog in a pill.
"Our exciting data at ADA 2019 reflect a deep commitment at Novo Nordisk to develop innovative treatment options that have the potential to transform the way clinicians and patients manage diabetes," said Todd Hobbs, vice president and US chief medical officer of Novo Nordisk. "With a focused approach and passion for pioneering scientific advancements, we continue to seek new options and approaches that address the needs of millions of patients living with this serious disease."
Semaglutide is a GLP-1 analog.1 Oral semaglutide is an investigational once-daily GLP-1 analog in a pill that is in development for the treatment of type 2 diabetes.
The PIONEER phase 3a global clinical trial program for oral semaglutide comprises 10 clinical trials that enrolled 9,543 adults with type 2 diabetes.